Compare BCPC & SRRK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BCPC | SRRK |
|---|---|---|
| Founded | 1967 | 2012 |
| Country | United States | United States |
| Employees | 1355 | N/A |
| Industry | Major Chemicals | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.8B | 4.9B |
| IPO Year | 1995 | 2018 |
| Metric | BCPC | SRRK |
|---|---|---|
| Price | $180.10 | $44.63 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 11 |
| Target Price | ★ $176.00 | $51.20 |
| AVG Volume (30 Days) | 141.8K | ★ 757.3K |
| Earning Date | 05-25-2026 | 04-10-2026 |
| Dividend Yield | ★ 0.53% | N/A |
| EPS Growth | ★ 20.87 | N/A |
| EPS | ★ 4.75 | N/A |
| Revenue | ★ $799,023,000.00 | N/A |
| Revenue This Year | $7.99 | N/A |
| Revenue Next Year | $2.77 | $21,831.23 |
| P/E Ratio | $37.81 | ★ N/A |
| Revenue Growth | ★ 13.56 | N/A |
| 52 Week Low | $139.17 | $22.71 |
| 52 Week High | $183.01 | $49.82 |
| Indicator | BCPC | SRRK |
|---|---|---|
| Relative Strength Index (RSI) | 63.71 | 44.17 |
| Support Level | $149.11 | $42.74 |
| Resistance Level | $183.01 | $48.79 |
| Average True Range (ATR) | 5.05 | 1.76 |
| MACD | -0.18 | -0.25 |
| Stochastic Oscillator | 81.61 | 8.71 |
Balchem Corp is engaged in the development, manufacture, and marketing of specialty performance ingredients and products for various industries. The company's reportable segments are; Human Nutrition and Health, which generates maximum revenue, and provides human-grade choline nutrients and mineral amino acid chelated products through this segment for nutrition and health applications; Animal Nutrition and Health, which provides nutritional products derived from its microencapsulation and chelation technologies in addition to the essential nutrient choline chloride; and the Specialty Products segment includes re-packaging and distributing several performance gases and chemicals. Geographically, the company derives its key revenue from the United States and the rest from foreign countries.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.